Natalizumab (Tysabri) Re-Initiation of Dosing

Clinical trial NCT00297232 · TERMINATED

Trial details

NCT number: NCT00297232
Sponsor: Biogen
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2006-03-01
Primary completion: 2014-04-01
Enrollment: 1094

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.